Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Discontinued
Reference number: GID-TA11007
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early September 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early November 2023.